10x Genomics Q4 revenue $166M (+1% YoY); FY26 guidance $600-625M

10x Genomics, Inc.

2025-FY EPS reported -$0.35 revenue$642,823,000

Q4 2025 revenue $166.0M (+1% YoY); FY25 $642.8M (+5%), ex-settlements $598.7M (-2%).
Q4 net loss $16.3M vs $49.0M loss YoY; FY25 net loss $43.5M vs $182.6M loss YoY.
Operating expenses down 18% Q4 and 17% FY; gross margin 68% Q4 and 69% FY.
FY2026 revenue guidance $600-625M (0-4% growth ex-2025 settlements).
Cash and equivalents $523.4M at year-end, up $130M vs prior year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.